Key Laboratory of Cardiovascular Disease and Molecular Intervention, Department of Physiology, Nanjing Medical University, Nanjing, China.
Acta Physiol (Oxf). 2014 Mar;210(3):534-45. doi: 10.1111/apha.12188. Epub 2013 Dec 5.
Salusin-β in paraventricular nucleus (PVN) increases renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP), heart rate (HR) and arginine vasopressin (AVP) release in hypertensive rats but not in normal rats. The present study was designed to investigate the downstream molecular mechanism of salusin-β in the PVN in hypertension.
Renovascular hypertension was induced by two-kidney, one-clip (2K1C) in male SD rats. Acute experiments were carried out 4 weeks after 2K1C or sham operation under anaesthesia.
MrgA1 mRNA expression and salusin-β level in the PVN as well as plasma salusin-β level were increased in 2K1C rats. Bilateral PVN microinjection of salusin-β increased the RSNA, MAP and HR in 2K1C rats, which were abolished by the pre-treatment with polyethylene glycol-superoxide dismutase (PEG-SOD), the superoxide anion scavenger tempol, the NAD(P)H oxidase inhibitor apocynin or the protein kinase C (PKC) inhibitor chelerythrine chloride (CLC), but not affected by the AT1 receptor antagonist losartan, the Mas receptor antagonist A-779, the NOS inhibitor L-NAME or the GABAA and GABAB receptor antagonists gabazine+CGP-35348. Salusin-β-induced increases in superoxide anion level and NAD(P)H oxidase activity in the PVN were abolished by the PVN pre-treatment with CLC. Salusin-β increased AVP levels in rostral ventrolateral medulla and plasma, which were prevented by the pre-treatment with PEG-SOD, apocynin or CLC in 2K1C rats. Salusin-β augmented the enhanced activity of PKC in the PVN in 2K1C rats.
Protein kinase C-NAD(P)H oxidase-superoxide anions pathway in the PVN is involved in salusin-β-induced sympathetic activation, pressor response and AVP release in renovascular hypertension.
在高血压大鼠中,室旁核(PVN)中的 Salusin-β 增加肾交感神经活性(RSNA)、平均动脉压(MAP)、心率(HR)和精氨酸加压素(AVP)释放,但在正常大鼠中则没有。本研究旨在探讨高血压大鼠 PVN 中 Salusin-β 的下游分子机制。
通过双肾一夹(2K1C)在雄性 SD 大鼠中诱导肾血管性高血压。在 2K1C 或假手术麻醉后 4 周进行急性实验。
2K1C 大鼠 PVN 中的 MrgA1 mRNA 表达和 Salusin-β 水平以及血浆 Salusin-β 水平升高。PVN 双侧微注射 Salusin-β 增加了 2K1C 大鼠的 RSNA、MAP 和 HR,这些作用被超氧化物歧化酶聚乙二醇(PEG-SOD)、超氧阴离子清除剂替普、NAD(P)H 氧化酶抑制剂 apocynin 或蛋白激酶 C(PKC)抑制剂氯化Chelerythrine(CLC)预处理所消除,但不受 AT1 受体拮抗剂 losartan、Mas 受体拮抗剂 A-779、NOS 抑制剂 L-NAME 或 GABA A 和 GABA B 受体拮抗剂 gabazine+CGP-35348 的影响。PVN 中 CLC 预处理消除了 Salusin-β 诱导的超氧阴离子水平和 NAD(P)H 氧化酶活性的增加。Salusin-β 增加了延髓头侧腹外侧区的 AVP 水平和血浆中的 AVP 水平,在 2K1C 大鼠中,这些作用被 PEG-SOD、apocynin 或 CLC 预处理所预防。Salusin-β 增强了 2K1C 大鼠 PVN 中 PKC 的增强活性。
PVN 中的蛋白激酶 C-NAD(P)H 氧化酶-超氧阴离子途径参与了 Salusin-β 诱导的肾血管性高血压中的交感神经激活、升压反应和 AVP 释放。